Literature DB >> 17548345

Mechanism of reversal of phospholamban inhibition of the cardiac Ca2+-ATPase by protein kinase A and by anti-phospholamban monoclonal antibody 2D12.

Zhenhui Chen1, Brandy L Akin, Larry R Jones.   

Abstract

Our model of phospholamban (PLB) regulation of the cardiac Ca(2+)-ATPase in sarcoplasmic reticulum (SERCA2a) states that PLB binds to the Ca(2+)-free, E2 conformation of SERCA2a and blocks it from transitioning from E2 to E1, the Ca(2+)-bound state. PLB and Ca(2+) binding to SERCA2a are mutually exclusive, and PLB inhibition of SERCA2a is manifested as a decreased apparent affinity of SERCA2a for Ca(2+). Here we extend this model to explain the reversal of SERCA2a inhibition that occurs after phosphorylation of PLB at Ser(16) by protein kinase A (PKA) and after binding of the anti-PLB monoclonal antibody 2D12, which recognizes residues 7-13 of PLB. Site-specific cysteine variants of PLB were co-expressed with SERCA2a, and the effects of PKA phosphorylation and 2D12 on Ca(2+)-ATPase activity and cross-linking to SERCA2a were monitored. In Ca(2+)-ATPase assays, PKA phosphorylation and 2D12 partially and completely reversed SERCA2a inhibition by decreasing K(Ca) values for enzyme activation, respectively. In cross-linking assays, cross-linking of PKA-phosphorylated PLB to SERCA2a was inhibited at only two of eight sites when conducted in the absence of Ca(2+) favoring E2. However, at a subsaturating Ca(2+) concentration supporting some E1, cross-linking of phosphorylated PLB to SERCA2a was attenuated at all eight sites. K(Ca) values for cross-linking inhibition were decreased nearly 2-fold at all sites by PLB phosphorylation, demonstrating that phosphorylated PLB binds more weakly to SERCA2a than dephosphorylated PLB. In parallel assays, 2D12 blocked PLB cross-linking to SERCA2a at all eight sites regardless of Ca(2+) concentration. Our results demonstrate that 2D12 restores maximal Ca(2+)-ATPase activity by physically disrupting the binding interaction between PLB and SERCA2a. Phosphorylation of PLB by PKA weakens the binding interaction between PLB and SERCA2a (yielding more PLB-free SERCA2a molecules at intermediate Ca(2+) concentrations), only partially restoring Ca(2+) affinity and Ca(2+)-ATPase activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548345     DOI: 10.1074/jbc.M703516200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Rhythmic beating of stem cell-derived cardiac cells requires dynamic coupling of electrophysiology and Ca cycling.

Authors:  Ihor Zahanich; Syevda G Sirenko; Larissa A Maltseva; Yelena S Tarasova; Harold A Spurgeon; Kenneth R Boheler; Michael D Stern; Edward G Lakatta; Victor A Maltsev
Journal:  J Mol Cell Cardiol       Date:  2010-10-15       Impact factor: 5.000

2.  Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure.

Authors:  Elizabeth L Lockamy; Razvan L Cornea; Christine B Karim; David D Thomas
Journal:  Biochem Biophys Res Commun       Date:  2011-04-12       Impact factor: 3.575

3.  Characterizing phospholamban to sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) protein binding interactions in human cardiac sarcoplasmic reticulum vesicles using chemical cross-linking.

Authors:  Brandy L Akin; Larry R Jones
Journal:  J Biol Chem       Date:  2012-01-14       Impact factor: 5.157

4.  Phospholamban binds with differential affinity to calcium pump conformers.

Authors:  Philip Bidwell; Daniel J Blackwell; Zhanjia Hou; Aleksey V Zima; Seth L Robia
Journal:  J Biol Chem       Date:  2011-08-09       Impact factor: 5.157

5.  The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum.

Authors:  Brandy L Akin; Thomas D Hurley; Zhenhui Chen; Larry R Jones
Journal:  J Biol Chem       Date:  2013-08-31       Impact factor: 5.157

6.  Phosphomimetic mutations increase phospholamban oligomerization and alter the structure of its regulatory complex.

Authors:  Zhanjia Hou; Eileen M Kelly; Seth L Robia
Journal:  J Biol Chem       Date:  2008-08-16       Impact factor: 5.157

7.  Allosteric regulation of SERCA by phosphorylation-mediated conformational shift of phospholamban.

Authors:  Martin Gustavsson; Raffaello Verardi; Daniel G Mullen; Kaustubh R Mote; Nathaniel J Traaseth; T Gopinath; Gianluigi Veglia
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

8.  Hydrophobic imbalance in the cytoplasmic domain of phospholamban is a determinant for lethal dilated cardiomyopathy.

Authors:  Delaine K Ceholski; Catharine A Trieber; Howard S Young
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

9.  Activation of AMP-activated protein kinase by metformin ablates angiotensin II-induced endoplasmic reticulum stress and hypertension in mice in vivo.

Authors:  Quanlu Duan; Ping Song; Ye Ding; Ming-Hui Zou
Journal:  Br J Pharmacol       Date:  2017-05-31       Impact factor: 8.739

10.  Intracellular calcium dynamics and acceleration of sinus rhythm by beta-adrenergic stimulation.

Authors:  Boyoung Joung; Liang Tang; Mitsunori Maruyama; Seongwook Han; Zhenhui Chen; Marcelle Stucky; Larry R Jones; Michael C Fishbein; James N Weiss; Peng-Sheng Chen; Shien-Fong Lin
Journal:  Circulation       Date:  2009-02-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.